The Salk Institute team uses a viral vector encoding four reprogramming factors to rejuvenate aging mouse cells, achieving a 30% lifespan increase by reversing cellular senescence. Concurrently, Life Biosciences plans human trials targeting optic nerve damage in NAION using similar gene rejuvenation methods.
Key points
- Polyviral vector delivers Yamanaka factors (Oct4, Sox2, Klf4, c-Myc) to aged mice, extending lifespan by 30%.
- Life Biosciences collaborates with Harvard researchers for first human gene rejuvenation trials targeting NAION via ocular injections.
- Complementary longevity strategies include senolytic drugs to clear senescent cells and telomere-lengthening approaches, each with unique safety profiles.
Why it matters: This work demonstrates direct cellular reprogramming as a viable strategy for aging intervention, paving the way for therapies that restore tissue function rather than merely managing symptoms.
Q&A
- What are Yamanaka factors?
- What is non-arteritic anterior ischemic optic neuropathy (NAION)?
- How do senolytics contribute to longevity research?
- Why are teratomas a concern in cellular reprogramming?
- What distinguishes radical longevity from healthspan research?